Quantum Blue®

The BÜHLMANN Quantum Blue® product line is based on lateral flow technology, offering results within minutes using the Quantum Blue®  reader to analyze the signal intensity from the test and control line to give a quantitative value. These rapid tests allow for the immediate measurement of calprotectin, CRP, MRP8/14, adalimumab, anti-adaliumab, infliximab,  and anti-infliximab. 

Calprotectin


Quantum Blue® fCAL lateral flow assays are designed for the quantitative determination of calprotectin in human stool specimens.  Quantum Blue® fCAL High Range and Quantum Blue® fCAL Extended are standardized with the BÜHLMANN fCAL® ELISA.

CRP


Quantum Blue® C-Reactive Protein (CRP) lateral flow assay is designed for the quantitative determination of c-reactive protein (CRP) in human serum.

 

MRP8/14


Quantum Blue® sCAL lateral flow assay is designed for the quantitative determination of MRP8/14 in human serum.

BUHLMANN-Calprotectin-Ascities_Quantum-Blue

Calprotectin-Ascites


Quantum Blue® Calprotectin Ascites assay is a reliable and rapid lateral flow assay for the determination of calprotectin concentrations in human ascites.

rsz_adalimumab_qb_horizontal_neu

Quantum Blue® Adalimumab


Quantum Blue® Adalimumab is the first rapid test to measure infliximab in serum samples. The lateral flow assay is designed for the selective measurement of adalimumab by a sandwich immunoassay in human serum samples.

BUHLMANN-Anti-Adalimumab_Anti-Infliximab

Quantum Blue® Anti-Adalimumab


Quantum Blue® Anti-Adalimumab is the fastest assay for anti-adalimumab antibody measurements in the market.  This lateral flow test is designed for the selective measurement of these antibodies by a sandwich immunoassay in human serum samples.

Quantum Blue® Infliximab


Quantum Blue® Infliximab is the first rapid test to measure infliximab. The lateral flow test is designed for the selective measurement of infliximab by a sandwich immunoassay in human serum samples.

Quantum Blue® Anti-Infliximab


Quantum Blue® Anti-Infliximab is the fastest assay for anti-adalimumab antibody measurements in the market. This lateral flow test is designed for the selective measurement of these antibodies by a sandwich immunoassay in human serum samples